Earnings Releases·Oct 29, 2026, 7:05 AM ET

Bristol Myers Squibb — Third Quarter 2026 Earnings Summary

Total revenues rose 7% year-over-year to $13.1 billion, driven by 12% growth in the Growth Portfolio and 9% U.S. revenue expansion, though Non-GAAP EPS declined 17% to $1.35 per share due to a $1.6 billion net charge from acquired IPRD and licensing income.
Full-year 2026 revenue guidance was raised to $49.75–$50.25 billion, and Non-GAAP EPS guidance was updated to $6.35–$6.55, reflecting strong momentum in key products like Eliquis (25% growth) and the Growth Portfolio.
Strategic capital allocation includes a $2.3 billion investment in a new manufacturing campus in Houston and a $173 million expansion of radiopharmaceutical operations in Indiana, alongside a net debt improvement to $29.9 billion.
The pipeline advanced with FDA approvals for Zenbexus and Camzyos, while positive topline results were reported for multiple late-stage assets including Izalontamab Brengitecan, pumitamig, and Zolacabtagene Autoleucel.